Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells

Abstract

Overall, we provide evidence that azoles exert their effect by targeting genes and pathways regulated by HK2. These findings shed light on the action of azoles in GBM. Combined with existing literature and preclinical results, these data support the value of repurposing azoles in GBM clinical trials.